DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Adjunctive Glycine for Obsessive Compulsive Disorder

Information source: Nathan Kline Institute for Psychiatric Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Obsessive Compulsive Disorder

Intervention: glycine (Dietary Supplement); placebo powder (Other)

Phase: N/A

Status: Completed

Sponsored by: Nathan Kline Institute for Psychiatric Research

Official(s) and/or principal investigator(s):
William M Greenberg, MD, Principal Investigator, Affiliation: Nathan Kline Institute for Psychiatric Research

Summary

The purpose of this study is to determine whether individuals with obsessive compulsive disorder who will take a preparation of the amino acid glycine in addition to their current treatment, may experience improvement in their symptoms.

Clinical Details

Official title: Adjunctive Glycine for Obsessive Compulsive Disorder

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Y-BOCS (Yale-Brown Obsessive Compulsive Scale)

Secondary outcome:

NIMC-OC scale

CGI-Improvement

QLS(Quality of Life Scale)

Sheehan Disability Scale

Detailed description: Individuals with obsessive compulsive disorder (OCD) often find inadequate relief, even with the best of currently available treatments. Some evidence suggests the the neurotransmitter glutamate may be a useful target for new treatments for OCD. The amino acid glycine, if given orally in adequate dosages, can have specific effects on one particular glutamate receptor molecule in the brain, that might be helpful with OC symptoms. This randomized, double-blind protocol will have study participants who suffer with OCD take either a glycine preparation or placebo for 12 weeks. Clinical measures (e. g., Y-BOCS, NIMH-OC) will be recorded at each visit to determine whether those taking the glycine experience clinical benefit.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of OCD present for at least 1 year

- Male or female, age 18 to 65

- Stable medication regimen for 12 weeks prior to study entry

- at least moderately severe OC symptoms

Exclusion Criteria:

- Active substance use disorder within the last 6 months

- Comorbid schizophrenia, schizoaffective disorder, bipolar disorder, tic disorder,

Tourette Disorder, schizotypal personality disorder

- Hoarding as the principal OCD symptom

- Insulin-dependent diabetes mellitus

- Pregnant or breastfeeding

Locations and Contacts

The Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962, United States
Additional Information

Starting date: June 2004
Last updated: August 21, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017